295 results about "Ocular hypertension" patented technology

A stent for treating ocular hypertension by providing means for enhancing outflows of aqueous humor from the anterior chamber. An exemplary stent is fabricated of a shape memory polymer (SMP) that can withstand very large reversible inelastic strains for storing energy in a temporary reduced cross-sectional shape. In one embodiment, the stent in a temporary shape is introduced into a targeted tissue volume in and about the eye's aqueous outflow pathways. Following minimally invasive implantation of the stent, body temperature or another stimulus causes the stent to move from its temporary shape to its memory shape thereby releasing stored energy to retract the tissue to open flow pathways or increase tissue permeability. In another embodiment, the SMP stent body has interior flow passageways to provide addition fluid outflow means. In several embodiments, the stent can be of a shape memory alloy material.

Presbyopia is treated by implanting within a plurality of elongated pockets formed in the tissue of the sclera of the eye transverse to a meridian of the eye, a prosthesis having an elongated body having a first surface and a second surface opposite the first surface to contact the base and flap of the scleral pocket. The first and second surfaces are spaced apart a distance so that the implanted prosthesis exerts an outward force on the flap of the scleral pocket which results in an outward traction on at least the anterior margin of the scleral pocket. The combined effect of the implanted prostheses is to exert a radially outward traction on the sclera in the region overlying the ciliary body which expands the sclera in the affected region together with the underlying ciliary body. The expansion of the ciliary body restores the effective working distance of the ciliary muscle in the presbyopic eye and thereby increases the amplitude of accommodation. Hyperopia, primary open angle glaucoma and / or ocular hypertension can be treated by increasing the effective working distance of the ciliary muscle according to the invention. A preferred embodiment of the scleral prosthesis has a major surface adapted to contact the base or flap of the pocket and an opposite surface or ridge spaced from the major surface.

An apparatus and technique for transscleral light-mediated biostimulation of the trabecular plates of a patient's eye in a treatment for glaucoma or ocular hypertension. The apparatus includes; (i) a working end geometry for contacting the anterior surface of the sclera and cornea to insure that a laser emission reaches the trabecular meshwork from a particular location on the anterior surface of the sclera, (ii) a laser energy source providing a wavelength appropriate for absorption beneath the anterior scleral surface to the depth of the trabecular plates, and (iii) a dosimetry control system for controlling the exposure of the laser emission at the particular spatial locations. The device uses a light energy source that emits wavelengths in the near-infrared portion of the spectrum, preferably in the range of about 1.30 mum to 1.40 mum or from about 1.55 mum to 1.85 mum. The depth of absorption of such wavelength ranges will extend through most, if not all, of the thickness of the sclera (750 mum to 950 mum). In accordance with a proposed method of trabecular biostimulation, the targeted region is elevated in temperature to a range between about 40° C. to 55° C. for a period of time ranging from about 1 second to 120 seconds or more.

Provided is a method for treating ocular hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an ophthalmic composition comprising latanoprost as an active ingredient thereof to a subject in need of said treatment, wherein the ophthalmic composition contains substantially no benzalkonium chloride.

Presbyopia is treated by implanting within a plurality of elongated pockets formed in the tissue of the sclera of the eye transverse to a meridian of the eye, a prosthesis having an elongated base member having an inward surface adapted to be placed against the inward wall of the pocket and having a ridge on the inward surface of the base extending along at least a major portion of the major dimension of the base. The combined effect of the implanted prostheses is to exert a radially outward traction on the sclera in the region overlying the ciliary body which expands the sclera in the affected region together with the underlying ciliary body. The expansion of the ciliary body restores the effective working distance of the ciliary muscle in the presbyopic eye and thereby increases the amplitude of accommodation. Hyperopia, primary open angle glaucoma and / or ocular hypertension can be treated by increasing the effective working distance of the ciliary muscle according to the invention.

Embodiments include methods, apparatuses, and systems for reducing elevated intraocular pressure (IOP) in a patient to either prevent or treat open-angle glaucoma. Heat is applied to the trabecular meshwork in the patient's eye without damaging proteins in the trabecular meshwork. The application of heat to the trabecular meshwork has the effect of relaxing or loosening protein clogs or other inhibitors in the trabecular meshwork, which are either reducing or obstructing of the outflow of aqueous humor, thereby increasing the patient's IOP and causing ocular hypertension (OHT). By loosening or relaxing clogs or other inhibitors in the trabecular meshwork, the outflow path for aqueous humor is increased or restored, which can lower IOP and either prevent or treat glaucoma. Force may also be applied to the patient's eye to apply pressure to the trabecular meshwork to further assist in the loosening or relaxing of clogs or other inhibitors in the trabecular meshwork.

RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.

The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).

The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and / or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

Method and systems for eye surgery for the treatment of presbyopia, ocular hypertension and glaucoma and other soft tissue surgeries are disclosed. System design parameters of lasing crystals (Nd:YAG, Nd:YLF, Er:YAG and Er:YSGG), nonlinear crystals (KTP, BBO, LBO), laser cavity configuration and energy delivery means are disclosed for diode-laser-pumped lasers with output wavelength at UV (263 or 266 nm), green (527 or 523 nm), and mid-IR (2.78 or 2.94 microns). Dual function of ablation and coagulation is proposed by a mode control means. The preferred diode-laser includes a wavelength at about 0.75 to 0.98 microns with power about 15 to 40 W and used in a side-pumping configuration to generate UV or IR having an energy per pulse about 3 to 30 mJ, power of about 0.1 to 1.5 W and operated at free running mode (IR laser) or pulsed mode (UV laser).

The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with other preventive or therapeutic drug for glaucoma or ocular hypertension, their intraocular pressure lowering effects are complemented and / or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.

The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a nucleoside 5′-pyrophosphate pyranoside or analogue, which is defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as found in glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with another therapeutic agent or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure. The present invention also provides a novel composition comprising a nucleoside 5′-pyrophosphate pyranoside or analogue.

Methods and compositions for controlling ocular hypertension associated with (i) primary open angle glaucoma (POAG), (ii) other forms of glaucoma, or (iii) glucocorticoid therapy are disclosed. The methods involve administration of angiostatic agents and other IOP-lowering agents via local injections in the anterior segment of the eye. The most preferred IOP-lowering agents are angiostatic steroids, particularly anecortave acetate, and the most preferred route of administration is an anterior juxtascleral injection or implant. The invention is based in part on the discovery that anterior juxtascleral injections of anecortave acetate are capable of controlling intraocular pressure for sustained periods of from one to several months or more. This result is believed to be attributable to facilitation of access of the anecortave acetate to the trabecular meshwork via the anterior juxtascleral route of administration. This route of administration is also believed to be advantageous for other types of IOP-lowering agents, particularly molecules that cannot readily penetrate the cornea due to size or other physical properties.

The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein the dashed line indicates the presence or absence of a bond, the hatched wedge indicates the α (down) configuration, and the solid triangle indicates the β (up) configuration;B is a single, double, or triple covalent bond;n is 0-6;X is CH2, S or O;Y is any pharmaceutically acceptable salt of CO2H, or CO2R, CONR2, NHCH2CH2OH, N(CH2CH2OH)2, CH2OR, P(O)(OR)2, CONRSO2R, SONR2, or R is H, C1-6 alkyl or C2-6 alkenyl;R2 and R3 are C1-6 linear alkyl which may be the same or different, and may be bonded to each other such that they form a ring incorporating the carbon to which they are commonly attached;R4 is hydrogen, R, C(═O)R, or any group that is easily removed under physiological conditions such that R4 is effectively hydrogen;R5 is hydrogen or R;R6 isiv) hydrogen;v) a linear or branched hydrocarbon containing between 1 and 8 carbon atoms, which may contain one or more double or triple bonds, or oxygen or halogen derivatives of said hydrocarbon, wherein 1-3 carbon or hydrogen atoms may be substituted by O or a halogen; orvi) aryloxy, heteroaryloxy, C3-8 cycloalkyloxy, C3-8 cycloalkyl, C6-10 aryl or C3-10 heteroaryl, wherein one or more carbons is substituted with N, O, or S; and which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C6-10 aryl, C3-10 heteroaryl, aryloxy, heteroaryloxy, C1-6 alkyl, OR, SR, and SO2R.Some of the compounds of the present invention and some of their methods of preparation are also novel an nonobvious.

Embodiments include methods, apparatuses, and systems for reducing elevated intraocular pressure (IOP) in a patient to either prevent or treat open-angle glaucoma. Heat is applied to the trabecular meshwork in the patient's eye without damaging proteins in the trabecular meshwork. The application of heat to the trabecular meshwork has the effect of relaxing or loosening protein clogs or other inhibitors in the trabecular meshwork, which are either reducing or obstructing of the outflow of aqueous humor, thereby increasing the patient's IOP and causing ocular hypertension (OHT). By loosening or relaxing clogs or other inhibitors in the trabecular meshwork, the outflow path for aqueous humor is increased or restored, which can lower IOP and either prevent or treat glaucoma. Force may also be applied to the patient's eye to apply pressure to the trabecular meshwork to further assist in the loosening or relaxing of clogs or other inhibitors in the trabecular meshwork.

The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;wherein a hatched line represents the alpha configuration, a triangle represents the beta configuration, a straight line, e.g. at the 9, 11 or 15 position represents either the alpha or beta configuration, a dotted line represents the presence or absence of a double bond; a wavy line represents a cis or trans bond;X is O, S, NH or (CH2)n;n is 0 or an integer of from 1 to 4;Y is C1-C5 n-alkyl, C3-C7 cycloalkyl, phenyl, furanyl, thienyl, pyridinyl, thiazolyl, benzothienyl, benzofaranyl, naphthyl, or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, N(R2)2, CO2R2 and OR2;Z is (CH2)n or a covalent bond;R is C1-C6 lower alkyl or Z-CF3 or mesylate or triflate;R1 is H, R2 or COR2;andR2 is H or C1-C5 lower alkyl or 9, 11 or 15 esters thereof.

A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

An ophthalmic formulation for the treatment of glaucoma and intraocular pressure with a prostaglandin compound of the F-series (PGF), and particularly a prodrug form of a PGF2α analog, such as an ester, amide, or internal lactone, wherein preservative is an antimicrobial peptide, such as lactoferrin. In particularly preferred embodiments, the prostaglandin compound is a macrocyclic internal 1,15-lactone, such as the 16-aryloxy prostaglandin analogs, illustratively fluprostenol or cloprstenol.

In vivo imaging may be used to assess a condition (e.g., a state of glaucoma or a state of ocular hypertension) of an eye of a living animal. A dye may be intravenously injected into the living animal. The dye may bind to amyloid in the nervous system of the animal. Images may be taken of a retina, an optic nerve head, an optic nerve, the lateral geniculate nucleus, and / or the visual cortex. Images may be taken using methods such as fluorescent angiography, magnetic resonance imaging, computed tomography, positron emission tomography, and / or single photon emission computed tomography. The condition of the eye and / or retinal ganglion cells in the eye may be assessed from one or more of the images. The condition of the eye may be assessed based on the presence of amyloid in one or more of the images.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

This invention relates to compositions and methods for lowering intraocular pressure and treatment and / or prevention of glaucoma and ocular hypertension. The invention provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin peptide and other products of protein / gene engineered modifications of insulin for the lowering of intraocular pressure. The invention also provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein / gene engineered modifications of insulin for increasing the success of glaucoma surgical procedures. The invention further provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein / gene engineered modifications of insulin for neuroprotection of retinal ganglion cells.

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w / v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.